Mark Carlson, MD
Internal Medicine · Cedar Park, TXNPI 1023008398
Payments from drug & device makers
Across 1,383 payments — averaging $4774.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$2M
- Vertex$1.7M
- Janssen Research & Development, LLC$966K
- Pfizer$472K
- Bavarian Nordic A/s$429K
- Sanofi Pasteur Inc.$351K
- plus $739K from 20 others
Across 2 payments — averaging $1844.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$4K
What the payments were for
- Food & beverage$357100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 1,103 | $1,962,550 |
| Vertex | 6 | $1,683,146 |
| Janssen Research & Development, LLC | 79 | $965,546 |
| Pfizer | 38 | $472,257 |
| Bavarian Nordic A/s | 36 | $429,211 |
| Sanofi Pasteur Inc. | 31 | $351,161 |
| Amgen | 5 | $257,296 |
| Eli Lilly | 3 | $187,541 |
| GSK | 20 | $133,466 |
| Radius Health, Inc. | 33 | $70,456 |
| AstraZeneca | 1 | $21,200 |
| Bristol Myers Squibb | 1 | $19,000 |
| Astrazeneca UK Limited | 2 | $18,653 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $14,500 |
| E.r. Squibb & Sons, L.L.C. | 10 | $12,305 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $4,000 |
| Eisai Inc. | 2 | $97 |
| Johnson & Johnson | 2 | $40 |
| Merck | 1 | $17 |
| Clovis Oncology, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Seagen Inc. | 1 | $11 |
How this compares
$6,602,542 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 13 | $11,218 |
| EliquisApixaban | 13 | $7,462 |
| Propranolol Hcl ErPropranolol Hcl | 28 | $1,535 |
| Donepezil Hcl | 53 | $1,006 |
| Potassium Chloride | 46 | $910 |
| Divalproex Sodium ErDivalproex Sodium | 17 | $871 |
| Duloxetine Hcl | 14 | $820 |
| Levothyroxine Sodium | 71 | $739 |
| Divalproex Sodium | 21 | $724 |
| Atorvastatin Calcium | 49 | $722 |
| Gabapentin | 45 | $702 |
| Memantine Hcl | 13 | $525 |
| Furosemide | 77 | $507 |
| Amlodipine Besylate | 47 | $501 |
| Diltiazem Hcl | 13 | $471 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $472,257 | $7,46213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Cedar Park
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.